Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 27;12:1046143. doi: 10.3389/fonc.2022.1046143

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liu, Tian, Yi, Feng, Chu, Liu, Zhang, Zhang and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The antitumor efficacy of co-treatment with PD and CTX in subcutaneous tumor models. (A) Subcutaneous tumor models of HCT116 and LoVo cells were collected after the mice were sacrificed. Each group contained five mice, but one mouse of the HCT116 control group died during the experiment. (B) After sacrifice, subcutaneous tumors were removed and photographed. (C) Tumor weight was measured using an electronic balance. The mean ± S.D. is shown. One-way ANOVA was performed used to analyze P values between groups. All groups are compared with the ‘control’ group, the ‘CTX’ group is compared with the ‘CTX+PD’ group. *P < 0.05 represents a significant difference. (D) Survival curves of each group. Survival days of other groups are compared with those of the control group; the ‘CTX’ group is compared with the ‘CTX+PD’ group. *P<0.05 represents a significant difference.